TARSUS PHARMACEUTICALS, INC. Equity Securities, FV-NI, Unrealized Loss
TARSUS PHARMACEUTICALS, INC. (TARS) reported Equity Securities, FV-NI, Unrealized Loss of $477.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-02-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesFvNiUnrealizedLoss · last filed 2025-02-25
- TARSUS PHARMACEUTICALS, INC. equity securities, fv-ni, unrealized loss for the quarter ending 2023-12-31 was -$421.00K, a 178.84% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. equity securities, fv-ni, unrealized loss for the quarter ending 2023-09-30 was $112.00K.
- TARSUS PHARMACEUTICALS, INC. equity securities, fv-ni, unrealized loss for the quarter ending 2023-06-30 was -$139.00K.
- TARSUS PHARMACEUTICALS, INC. equity securities, fv-ni, unrealized loss for the quarter ending 2023-03-31 was $925.00K.
- TARSUS PHARMACEUTICALS, INC. equity securities, fv-ni, unrealized loss for fiscal 2023 was $477.00K, a 44.53% decline from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. equity securities, fv-ni, unrealized loss for fiscal 2022 was $860.00K, a 45.52% increase from fiscal 2021.
- TARSUS PHARMACEUTICALS, INC. equity securities, fv-ni, unrealized loss for fiscal 2021 was $591.00K.
| Period end | Equity Securities, FV-NI, Unrealized Loss 3 month | Equity Securities, FV-NI, Unrealized Loss 6 month | Equity Securities, FV-NI, Unrealized Loss 9 month | Equity Securities, FV-NI, Unrealized Loss 12 month | Equity Securities, FV-NI, Unrealized Loss 12 month as first filed |
|---|---|---|---|---|---|
| 2023-12-31 | -$421.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$309.00K derived: sum of 2 quarters · filed 2025-02-25 | -$448.00K derived: sum of 3 quarters · filed 2025-02-25 | $477.00K 10-K · filed 2025-02-25 | |
| 2023-09-30 | $112.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$27.00K derived: sum of 2 quarters · filed 2023-11-09 | $898.00K 10-Q · filed 2023-11-09 | $1.43M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2023-06-30 | -$139.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $786.00K 10-Q · filed 2023-08-10 | $1.32M derived: sum of 3 quarters · filed 2024-02-27 | ||
| 2023-03-31 | $925.00K 10-Q · filed 2023-05-09 | $1.46M derived: sum of 2 quarters · filed 2024-02-27 | |||
| 2022-12-31 | $534.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $860.00K 10-K · filed 2024-02-27 | $268.00K 10-K · filed 2023-03-17 | ||
| 2022-09-30 | $326.00K 10-Q · filed 2022-11-09 | ||||
| 2021-12-31 | $591.00K 10-K · filed 2023-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |